The Hindu Business Line : Novartis receives exclusive marketing rights for Glivec

NOVARTIS India Ltd (NIL) has become the first pharmaceutical company in India to be granted exclusive marketing rights for its oncology drug, Glivec, by the Controller General of Patents and Trademarks of India.

"The granting of the first pharma `exclusive rights' marks the beginning of a new chapter in the history of patents in India. This is a positive signal to the international community that India is progressing towards meeting all its obligations under TRIPs," Mr Ranjit Shahani, Vice-Chairman and Managing Director of the company told press persons here on Wednesday.

Describing Glivec as a breakthrough product in the treatment of cancer, he said it was one of the first oncology drugs that validate rational drug design based on an understanding of how some cancer cells work.

It is a signal transduction inhibitor, which potentially interferes with the pathways that signal the growth of tumour cells, he pointed out.

Article E-Mail :: Comment :: Syndication

Stories in this Section
Linc Pen to manufacture Mitsubishi products

No plans to set up unit in US now: Elgi

Novartis receives exclusive marketing rights for Glivec

Residency Hotel to offer service apartments

LG Pune factory to be made export hub

Handicrafts Export Corpn presents dividend cheque

Apollo Hospitals brings out CD on laparoscopic surgery

Natco to challenge grant of exclusive rights to Novartis cancer drug

Norms tightened for external borrowings — End-use conditions read tough

Corporates yet to heed RBI advice on hedging exposures